{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:11:12Z","timestamp":1761513072434,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.maturitas.2011.11.010","type":"journal-article","created":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T09:42:18Z","timestamp":1323942138000},"page":"194-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosis"],"prefix":"10.1016","volume":"71","author":[{"given":"Santiago","family":"Palacios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Brincat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Tamer","family":"Erel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Gambacciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Lambrinoudaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette H.","family":"Moen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Schenck-Gustafsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Tremollieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Vujovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"December (Suppl 2)","key":"10.1016\/j.maturitas.2011.11.010_bib0005","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S1297-319X(10)70004-X","article-title":"Osteoporosis and mortality","volume":"77","author":"Leboime","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0010","unstructured":"World Health Organization. http:\/\/www.who.int\/nutrition\/topics\/5_population_nutrient\/en\/index25.html [accessed 08.11.11]."},{"issue":"12","key":"10.1016\/j.maturitas.2011.11.010_bib0015","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","article-title":"Requirements for DXA for the management of osteoporosis in Europe","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"year":"2009","series-title":"Management of the menopause","author":"Rees","key":"10.1016\/j.maturitas.2011.11.010_bib0025"},{"issue":"June (2)","key":"10.1016\/j.maturitas.2011.11.010_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.maturitas.2010.02.008","article-title":"Treatment of osteoporosis with denosumab","volume":"66","author":"Lewiecki","year":"2010","journal-title":"Maturitas"},{"issue":"February (2)","key":"10.1016\/j.maturitas.2011.11.010_bib0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.maturitas.2010.10.010","article-title":"Bisphosphonates and oesophageal cancer risk: where are we now?","volume":"68","author":"Rozenberg","year":"2011","journal-title":"Maturitas"},{"issue":"October (2)","key":"10.1016\/j.maturitas.2011.11.010_bib0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2010.05.009","article-title":"SERMs: progress and future perspectives","volume":"67","author":"Pickar","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0045","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0050","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0055","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","journal-title":"Lancet"},{"issue":"October (6)","key":"10.1016\/j.maturitas.2011.11.010_bib0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ctrv.2007.04.005","article-title":"Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?","volume":"33","author":"Ding","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"September (9)","key":"10.1016\/j.maturitas.2011.11.010_bib0065","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"issue":"February (2)","key":"10.1016\/j.maturitas.2011.11.010_bib0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00198-005-2030-1","article-title":"Anti-vertebral fracture efficacy of raloxifene: a meta-analysis","volume":"17","author":"Seeman","year":"2006","journal-title":"Osteoporos Int"},{"issue":"September (9)","key":"10.1016\/j.maturitas.2011.11.010_bib0075","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"23","key":"10.1016\/j.maturitas.2011.11.010_bib0080","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"issue":"June (6)","key":"10.1016\/j.maturitas.2011.11.010_bib0085","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"National Surgical Adjuvant Breast and Bowel Project, Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.maturitas.2011.11.010_bib0095","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/CIRCULATIONAHA.108.817577","article-title":"Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors","volume":"119","author":"Collins","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0100","first-page":"558","article-title":"Adverse events reported by postmenopausal women in controlled trials with raloxifene","volume":"93","author":"Davies","year":"1999","journal-title":"Obstet Gynecol"},{"issue":"July (1)","key":"10.1016\/j.maturitas.2011.11.010_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajog.2003.10.701","article-title":"Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate","volume":"191","author":"Palacios","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0110","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0115","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0120","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","author":"Silverman","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0125","unstructured":"Palacios S, Silverman S, Levira A, Pallay A, Kaufman J, Brown J, et al. Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study. Presented at: 13th International Menopause Society World Congress on Menopause, June 8\u201311, 2011. Rome, Italy [Abstract 973]."},{"issue":"September (3)","key":"10.1016\/j.maturitas.2011.11.010_bib0130","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"issue":"March (2)","key":"10.1016\/j.maturitas.2011.11.010_bib0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/gme.0b013e3181b7c65f","article-title":"A randomized, placebo- and active-controlled trial of bazedoxifene\/conjugated estrogens for treatment of moderate to severe vulvar\/vaginal atrophy in postmenopausal women","volume":"17","author":"Kagan","year":"2010","journal-title":"Menopause"},{"issue":"September (3)","key":"10.1016\/j.maturitas.2011.11.010_bib0140","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2474-11-130","article-title":"Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis","volume":"11","author":"Christiansen","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"issue":"February (2)","key":"10.1016\/j.maturitas.2011.11.010_bib0150","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","article-title":"Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial","volume":"22","author":"De Villiers","year":"2011","journal-title":"Osteoporos Int"},{"issue":"16","key":"10.1016\/j.maturitas.2011.11.010_bib0155","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1021\/jm980048b","article-title":"Discovery and preclinical pharmacology of a novel, potent, non-steroidal estrogen receptor agonist\/antagonist, CP-336156, a diaryltetrahydronaphthalene","volume":"41","author":"Rosati","year":"1998","journal-title":"J Med Chem"},{"issue":"April (4)","key":"10.1016\/j.maturitas.2011.11.010_bib0160","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/endo.139.4.5902","article-title":"Effects of CP-336,156, a new, non-steroidal estrogen agonist\/antagonist, on bone, serum cholesterol, uterus and body composition in rat models","volume":"139","author":"Ke","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0165","unstructured":"FABLYN\u00ae (lasofoxifene tartrate). 0.5mg tablets, NDA22-242, Reproductive Health Drugs Advisory Committee Briefing Document. Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-829 4381b1-02-Pfizer.pdf; 2008 [accessed on 25.02.11]."},{"key":"10.1016\/j.maturitas.2011.11.010_bib0170","unstructured":"Fablyn\u00ae (lasofoxifene tartrate). Summary of product characteristics. Pfizer. Final Summary Minutes, Advisory Committee for Reproductive Health Drugs Meeting. Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/minutes\/2008-4381m1-final.pdf; 2008 [accessed on 25.03.11]."},{"issue":"8","key":"10.1016\/j.maturitas.2011.11.010_bib0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.maturitas.2011.11.010_bib0180","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2011.11.010_bib0185","unstructured":"Final Summary Minutes, Advisory Committee for Reproductive Health Drugs Meeting. Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/minutes\/2008-4381m1-final.pdf; 2008 [accessed on 25.03.11]."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512211003951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512211003951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:53:32Z","timestamp":1759913612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512211003951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0378512211003951"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2011.11.010","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2011.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}